-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Friends, new wonderful
.
On November 5, 2022, the 16th "Filipino Salon" hosted by Ipsen China was successfully held
online.
This conference invited several authoritative experts to gather online, closely follow the international prostate cancer academic trends, discuss and share the latest and hottest academic topics, practice the concept of DTR deep ketone reduction and PSA synchronous monitoring, double standard parallelism, and build dreams of Filipino Yue forward
.
The chairmen of this conference are Professor Chong Tie from the Second Affiliated Hospital of Xi'an Jiaotong University and Professor Liu Ben from the First Affiliated Hospital of Zhejiang University School of Medicine.
With the enthusiastic speeches of the two professors, the sixteenth "Filipino Salon of Vietnamese" kicked off:
Continuing the tradition of "Filipino Vietnamese", the conference is still divided into two parts, "Hot Topics Collide" and "Innovative Cross-Interface View"
.
The first session "Hot Topics Confrontation" focuses on the latest frontier progress in the field of prostate cancer, hosted by Professor Chong Tie
.
First of all, Professor Zhu Yanjun from Zhongshan Hospital Affiliated to Fudan University brought the "2022 International Conference on Prostate Cancer Endocrine Therapy" based on a global perspective, Professor Zhu outlined that the latest international research in 2022 released a number of blockbuster studies focusing on endocrine therapy for prostate cancer - ADT is still the cornerstone of prostate cancer treatment: there are still a variety of unmet needs for prostate cancer treatment; A number of important studies have confirmed that endocrine therapy for prostate cancer with ADT as the cornerstone improves the survival of patients; Triple therapy has become a new mode of prostate cancer treatment; PSA and testosterone levels
need to be continuously monitored and managed during ADT therapy.
Triptorelin continues to steadily reduce PSA and testosterone levels in prostate cancer patients, helping nearly 90% of prostate cancer patients to deeply lower ketone to testosterone levels <10ng/dl1, improving the quality of life of prostate cancer patients2
.
Subsequently, Professor Qiu Xuefeng from Gulou Hospital Affiliated to Nanjing University School of Medicine introduced the "2022 International Conference on Surgical Treatment of Prostate Cancer"
。 He shared that prostate cancer surgery still focuses on robotic-assisted radical prostatectomy, combined with continuous improvement of new technologies, to promote the continuous development of prostate cancer surgery technology; Guidelines recommend: ePLND is required for patients with intermediate and high-risk localized and locally advanced prostate cancer, and risk stratification tools and imaging results can accurately identify lymph nodes, guide lymph node dissection, and improve survival; Preoperative evaluation and choice of modality in urology can improve postoperative tumor outcome, continuation, sexual function, and quality of life
.
Continuous improvement of surgical methods, new technologies and postoperative multidisciplinary treatment are to improve patient outcomes and bring more benefits
to patients.
The last speaker of the first session was Professor Yao Lin from Peking University First Hospital, who shared the clinical value of 3-month dosage form treatment of prostate cancer with Daffelin ®, he said that the incidence of prostate cancer is increasing rapidly, most mHSPC patients will progress to mCRPC within 1-2 years, the economic burden of patients is heavy, advanced prostate cancer will affect the physical and mental health of patients for a long time, and the quality of life of patients will be significantly reduced; There is still an unmet demand for the treatment of locally advanced or metastatic prostate cancer in China, the availability of deep ketone-lowering drugs is low, the rate of bone metastasis is increasing, the frequency of visits is high, the economic burden is heavier, the proportion of patients with LUTS is >90%, the quality of life and compliance of patients with frequent injection are low, and long-acting dosage forms with low injection frequency are urgently needed; Triptorelin is closer to natural LHRH 3,4, has stronger affinity, and the efficacy and safety of the3-month dosage form in the treatment of advanced prostate cancer are similar to those of the 1M dosage form5, and the acceptance and compliance of advanced PCa patients are higher, and it can better meet the many clinical needs of prostate cancer patients6
.
In the discussion session of Session1, Professor Gao Xu from Shanghai Changhai Hospital, Professor Lin Yi from Tianjin Medical University General Hospital, Professor Li Wei from the First Affiliated Hospital of Xiamen University, and Professor Sun Yi from Shaanxi Provincial People's Hospital He spoke successively and discussed the latest progress in endocrine therapy for metastatic prostate cancer with ADT as the cornerstone around the latest research of the 2022 international academic conference, and expressed his views
on the advantages of ADT combination therapy in delaying disease progression and improving survival.
The second session of the conference, "Cross-Interface View of Innovation", focused on the topic of innovation and cross-border, and was chaired by Professor Liu Ben from the First Affiliated Hospital of Zhejiang University School of Medicine.
Professor Chen Zhaohui from Union Hospital Affiliated to Huazhong University of Science and Technology brought "Double Standards in Parallel, Shaping the Classics - Reinterpretation of Prostate Cancer Endocrine Treatment Goals", he said that more than half of newly diagnosed prostate cancer patients in China have metastatic prostate cancer, and prolonging survival and improving quality of life are the treatment goals; Both testosterone and PSA are important indicators of disease progression and survival, and simultaneous detection of testosterone and PSA can help clinical practice.
The guidelines and diagnosis and treatment standards emphasize that the lower the testosterone level, the better, the higher the survival benefit of prostate cancer patients, and the deep ketone lowering to a lower level is the trend of endocrine therapy.
Triptorelin helps more than 99% of patients reduce PSA<4ng/ml, and helps 90% of patients deeply reduce testosterone T<10ng/dl7; Triptorelin reduces the risk of death, improves survival, and improves overall quality of life8
.
The last topic of this conference was "Molecular Imaging-Mediated Precision Medicine for Prostate Cancer" by Professor Wang Feng from Nanjing First Hospital
。 He said that the integration of diagnosis and treatment showed very good prospects in the clinical diagnosis and treatment of prostate cancer; Nuclear medicine imaging determines the biological behavior of PCa, develops and develops the metastasis mechanism, and guides treatment.
PSMA directs precision surgery; Nuclear medicine treatment + immunotherapy plays a very important role in the treatment of prostate cancer; The prospect of alpha + beta therapy and PRLT as neoadjuvant therapy was analyzed and prospected, and more specific markers of prostate cancer were
sought.
In Session 2, Professor Yang Tiejun from Henan Cancer Hospital, Professor He Weiyang from the First Affiliated Hospital of Chongqing Medical University, Professor Zhou Feng from the First Affiliated Hospital of Zhejiang University School of Medicine, and Professor Ye Huamao from Shanghai Changhai Hospital The changes in PSA and testosterone levels during ADT treatment are the key to the treatment of prostate cancer patients, and the concept of reducing testosterone to a lower level has gradually received attention, and experts shared how to optimize the synchronous monitoring standards
of PSA and testosterone based on their clinical experience.
Finally, Professor Liu Ben, one of the chairs of the conference, made a concluding speech, Professor Liu thanked the speakers for their rich content, as well as the heated discussion of the discussion panel, and finally spoke highly of Ipsen China for providing an excellent academic exchange platform, he said that through such a conference, everyone can grasp the latest international diagnosis and treatment progress
in prostate cancer very quickly and very well 。 Through the wonderful explanations and wonderful discussions of experts, and some collisions of ideas and views, it has brought a very big gain
to everyone.
It is hoped that the Filipinos can continue to do so for a long time, and look forward to meeting with experts and scholars again to exchange academics
.
With the smooth handover of the Filipino Vietnamese, which symbolizes the "Dream Builder of the Philippines Moving Forward", the sixteenth phase of the "Filipino Belgian Salon" came to a successful conclusion
.
Experts from Beijing, Tianjin, Shanghai, Xiamen, Hangzhou, Xi'an, Nanjing, Wuhan and other places spoke freely in the field of prostate cancer, fully communicated, collided with sparks, and stirred new knowledge
.
At the same time, we continue to expand our online platforms and mainstream media channels to build a three-dimensional communication matrix to help boost brand voice
.
The whole process of the Yimaitong platform is broadcast synchronously, covering 2000+
experts in the field of urology.
Next stop, let's gather in Chengdu with experts to continue the Filipino Vietnamese journey!
References:
1.
Shim M, et al.
Investig Clin Urol.
2019 Jul; 60(4):244-250.
2.
Kao CC, Chang YH, Wu T, et al.
J Chin Med Assoc.
2012 Jun; 75(6):255-61.
3.
PubChem compound summary triptorelin [Internet].
US National Library of Medicine – National Center for Biotechnology Information; 4.
Song Yun, et al.
Synthetic Chemistry, 2010,18(02): 141-147+167 5.
Teillac P, et al.
Horm Res.
2004; 62(5):252-8.
6.
Li Ningchen, et al.
Chinese Journal of Surgery.
2008,46(21):1653-7 7.
Myungsun Shim, et al.
Investig Clin Urol Posted online 2019.
5.
21.
8.
Lesley Uttley, et al.
Evidence Review Group’s Report.
ScHARR.
2013:79.
Approval number: DIP-CN-010449 Valid until 2024-11-6
Click "Read more" to explore more prostate cancer exciting content
.
